Idiopathic Pulmonary Fibrosis Pipeline Review H2 2015

1. Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 01-Nov-2015 Single User License: US $2000 Browse more Reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

2. Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015 This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

3. Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research: AdAlta Pty Ltd., Aeolus Pharmaceuticals, Inc., Afferent Pharmaceuticals, Inc., AnaMar AB, Biogen, Inc., Bioneer Corporation, BiOrion Technologies B.V., Bristol-Myers Squibb Company, Carolus Therapeutics, Inc., Celgene Corporation, Chong Kun Dang Pharmaceutical Corp., Compugen Ltd., F. Hoffmann-La Roche Ltd., FibroGen, Inc., Galapagos NV, GenKyoTex S.A., Gilead Sciences, Inc., Global Blood Therapeutics, Inc., HanAll Biopharma Co., Ltd., HEC Pharm Co., Ltd., Histocell S.L., iBio, Inc., ImmuneWorks, LLC, Inventiva SAS, Isarna Therapeutics GmbH, Kadmon Corporation, LLC, Kasiak Research Private Limited, Kyorin Pharmaceutical Co., Ltd., LTT Bio-Pharma Co., Ltd., MedImmune, LLC, Moerae Matrix, Inc., MorphoSys AG, MSM Protein Technologies, Inc., Pacific Therapeutics Ltd., Pharmaxis Limited, Progenra, Inc., Promedior, Inc., ProMetic Life Sciences Inc., Pulmatrix, Inc., Respira Therapeutics, Inc., Rhizen Pharmaceuticals SA, Ribomic Inc., Sanofi, Teva Pharmaceutical Industries Limited and Yuhan Corporation ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

4. Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015 Drugs Profile Discussed in this Research: (pentoxifylline + acetylcysteine), AEOL-10150, AF-219, AM-0010, AMAP-102, Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis, Antisense RNAi Oligonucleotide for COPD and IPF, Antisense RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis, BG-00011, BMS-986020, BOT-191, CC-539, CC-90001, CGEN-25009, CKD-942, CMYJH-01, CT-2009, D-9030, Drug to Inhibit Galectin-3 for Fibrosis, FG-3019, GBT-1118, GBT-440, GKT-831, GLPG-1690, HC-016, HEC-00000585, HL-156FIB, HR-017, IBIOCFB-03, ICG-001, ISTH-0047, IVA-337, IW-001, KBP-7018, KD-025, lebrikizumab, LT-0011, LTI-03, MMI-0100, MOR-107, MSM-735, NAS-911, Neumomir, OLX-201, P-013, PBF-1129, PBI-4050, PBI-4425, pirfenidone, PRM-151, PUR-1500, PXS-4820, RBM-005, RBM-006, Refacell-IPF, RP-6503, RT-234, SAR-156597, SD-560, simtuzumab, Small Molecule for Idiopathic Pulmonary Fibrosis, Small Molecule for Idiopathic Pulmonary Fibrosis, Small Molecules for COPD and IPF, Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis, Small Molecules to Inhibit LOXL2 for Oncology and Idiopathic Pulmonary Fibrosis, Small Molecules to Inhibit PTPN13 for Idiopathic Pulmonary Fibrosis, Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis, SPL-334, Stem Cell Therapy for Idiopathic Lung Fibrosis, Stem Cell Therapy for Idiopathic Pulmonary Fibrosis, Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders, TD-139, tipelukast, tralokinumab, YH-siRNA1, ZL-2101, ZL-2102 ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

5. Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015 Scope For Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015 • The report provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Idiopathic Pulmonary Fibrosis and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Idiopathic Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects • Coverage of the Idiopathic Pulmonary Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type • Latest news and deals relating related to pipeline products ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

6. Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

7. Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441